Outcome of the Board Meeting dated 13th August 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals' board approved unaudited standalone results for Q1 FY26 (quarter ended June 30, 2025) with an unmodified opinion from auditor Dileep & Prithvi. Revenue from operations stood at Rs 1,665.90 lakhs versus Rs 1,704.54 lakhs in Q1 FY25, a mild dip of about 2.3%. Profit after tax rose to Rs 22.33 lakhs from Rs 16.69 lakhs, a growth of around 34% year-on-year, with EPS at Rs 0.23 versus Rs 0.17. The board also approved the 40th AGM on September 30, 2025 via video conferencing, fixed September 18, 2025 as the record date for dividend eligibility, and proposed continuing material related party transactions with Sandu Brothers Pvt Ltd for shareholder approval. CFO Vijay Kajarekar's continuation beyond age 70 was also recommended, subject to shareholder nod.
Mixed signals for shareholders: modest revenue softness offset by solid profit growth, plus a dividend record date set for mid-September. The related party transaction proposal with Sandu Brothers Pvt Ltd is worth watching as it requires shareholder voting at the AGM.